News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
64,451 Results
Type
Article (3020)
Company Profile (9)
Press Release (61422)
Section
Business (20621)
Career Advice (60)
Deals (3313)
Drug Delivery (3)
Drug Development (10254)
Employer Resources (1)
FDA (1406)
Job Trends (1534)
News (33841)
Policy (2229)
Tag
Academia (233)
Accelerated approval (9)
Adcomms (4)
Allergies (26)
Alliances (2266)
ALS (35)
Alzheimer's disease (247)
Antibody-drug conjugate (ADC) (59)
Approvals (1546)
Artificial intelligence (37)
Autoimmune disease (29)
Automation (2)
Bankruptcy (8)
Best Places to Work (1574)
BIOSECURE Act (1)
Biosimilars (17)
Biotechnology (8)
Bladder cancer (37)
Brain cancer (7)
Breast cancer (168)
Cancer (1013)
Cardiovascular disease (83)
Career advice (45)
CAR-T (49)
CDC (1)
Cell therapy (110)
Cervical cancer (7)
Clinical research (9331)
Collaboration (155)
Compensation (28)
Complete response letters (5)
COVID-19 (271)
CRISPR (12)
C-suite (40)
Cystic fibrosis (26)
Data (1431)
Depression (35)
Diabetes (78)
Diagnostics (642)
Digital health (5)
Diversity (1)
Drug discovery (24)
Drug pricing (14)
Duchenne muscular dystrophy (60)
Earnings (17589)
Editorial (2)
Employer resources (1)
Events (10335)
Executive appointments (35)
FDA (2104)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (7)
Funding (142)
Gene editing (33)
Generative AI (3)
Gene therapy (113)
GLP-1 (125)
Government (236)
Grass and pollen (1)
Guidances (172)
Healthcare (1782)
HIV (5)
Huntington's disease (4)
IgA nephropathy (18)
Immunology and inflammation (29)
Immuno-oncology (9)
Indications (24)
Infectious disease (315)
Inflammatory bowel disease (30)
Influenza (26)
Intellectual property (28)
Interviews (12)
IPO (2475)
IRA (5)
Job creations (80)
Job search strategy (32)
JPM (7)
Labor market (3)
Layoffs (35)
Leadership (1)
Legal (301)
Liver cancer (17)
Longevity (2)
Lung cancer (142)
Lymphoma (92)
Manufacturing (45)
MASH (28)
Medical device (1460)
Medtech (1466)
Mergers & acquisitions (949)
Metabolic disorders (171)
Multiple sclerosis (34)
NASH (1)
Neurodegenerative disease (58)
Neuropsychiatric disorders (18)
Neuroscience (467)
NextGen: Class of 2026 (441)
Non-profit (195)
Now hiring (1)
Obesity (62)
Opinion (18)
Ovarian cancer (52)
Pain (32)
Pancreatic cancer (40)
Parkinson's disease (43)
Partnered (2)
Patents (37)
Patient recruitment (84)
Peanut (15)
People (2040)
Pharmaceutical (4)
Pharmacy benefit managers (1)
Phase 1 (3013)
Phase 2 (4129)
Phase 3 (3338)
Pipeline (1273)
Policy (18)
Postmarket research (275)
Preclinical (1091)
Press Release (3)
Prostate cancer (46)
Psychedelics (12)
Radiopharmaceuticals (55)
Rare diseases (132)
Real estate (202)
Recruiting (1)
Regulatory (2390)
Reports (4)
Research institute (156)
Resumes & cover letters (21)
Rett syndrome (10)
RSV (17)
Schizophrenia (29)
Series A (30)
Series B (13)
Service/supplier (2)
Sickle cell disease (16)
Special edition (2)
Spinal muscular atrophy (24)
Sponsored (7)
Startups (210)
Stomach cancer (2)
Supply chain (3)
Tariffs (1)
The Weekly (1)
Vaccines (112)
Venture capital (6)
Weight loss (37)
Women's health (13)
Worklife (1)
Date
Today (21)
Last 7 days (91)
Last 30 days (274)
Last 365 days (4708)
2026 (370)
2025 (4758)
2024 (5201)
2023 (5797)
2022 (6235)
2021 (6258)
2020 (5359)
2019 (3841)
2018 (2860)
2017 (2608)
2016 (1823)
2015 (2274)
2014 (1666)
2013 (980)
2012 (1031)
2011 (1201)
2010 (1023)
Location
Africa (36)
Alabama (8)
Alaska (1)
Arizona (39)
Asia (4315)
Australia (567)
California (1491)
Canada (479)
China (181)
Colorado (51)
Connecticut (87)
Delaware (130)
Europe (9410)
Florida (221)
Georgia (53)
Idaho (2)
Illinois (183)
India (10)
Indiana (105)
Iowa (2)
Japan (122)
Kansas (3)
Kentucky (7)
Louisiana (9)
Maine (15)
Maryland (152)
Massachusetts (1166)
Michigan (31)
Minnesota (68)
Mississippi (3)
Missouri (20)
Montana (4)
Nebraska (1)
Nevada (19)
New Hampshire (14)
New Jersey (601)
New York (432)
North Carolina (179)
Northern California (782)
Ohio (39)
Oklahoma (3)
Oregon (4)
Pennsylvania (452)
Puerto Rico (4)
Rhode Island (2)
South America (61)
South Carolina (2)
Southern California (588)
Tennessee (12)
Texas (219)
United States (5884)
Utah (44)
Virginia (10)
Washington D.C. (5)
Washington State (148)
Wisconsin (18)
64,451 Results for "101".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
January 22, 2026
·
4 min read
Press Releases
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
January 27, 2026
·
2 min read
Press Releases
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
February 6, 2026
·
2 min read
Press Releases
Final APEX Phase 1b Clinical Results for Kodiak’s KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
February 4, 2026
·
4 min read
Press Releases
Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
December 16, 2025
·
5 min read
Press Releases
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
January 20, 2026
·
7 min read
Press Releases
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
January 12, 2026
·
3 min read
Press Releases
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
December 16, 2025
·
7 min read
Press Releases
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
February 10, 2026
·
6 min read
Press Releases
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
December 12, 2025
·
6 min read
1 of 6,446
Next
